GSK Bio
NEWS
A new method of synthesizing molecule arrangements in medicine could change the way many drugs, including the PARP inhibitor Zejula, a treatment for ovarian cancer, are produced.
The Dementia Discovery Fund this week welcomed more than 100 key stakeholders to its Annual Forum to discuss the opportunities and challenges surrounding the development of high-impact therapeutics for age-related dementias.
Companies strengthen their leadership teams and boards of directors with these appointments.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
Nadhim Zahawi MP has announced that Stevenage Bioscience Catalyst (SBC) has been successful in its application to become a Life Science Opportunity Zone.
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week’s appointments.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
Research from the Wellcome Sanger Institute, GSK and Biogen, under the Open Targets initiative, has shown that thousands of differences in DNA between individuals, associated with immune diseases, are linked with the switching-on of a specific subtype of immune cells.
Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
JOBS
IN THE PRESS